BLEOMYCIN-IFOSFAMIDE-CIS-PLATINUM (BIP) IN PELVIC RECURRENCE OF PREVIOUSLY IRRADIATED CERVICAL-CARCINOMA - A 2ND LOOK

被引:33
作者
RAMM, K
VERGOTE, IB
KAERN, J
TROPE, CG
机构
关键词
D O I
10.1016/0090-8258(92)90256-I
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The response rate and survival obtained with the combined regimen of bleomycin, ifosfamide, and cis-platinum (BIP) were analyzed in a series of 24 patients with recurrent cervical carcinoma in previously irradiated area. The doses were 30 mg, 5000 mg/m2, and 50 mg/m2, respectively. Mesna was given simultaneously (6000 mg/m2). None of the patients were treated with prior chemotherapy. All the patients were evaluable for toxicity and 20 for response. The median survival in patients evaluable for response was 9 months. No complete and 3 partial responses (15%) were observed, with a median duration of survival of 10 + months (range, 9 + -16). Stable disease was observed in 8 patients (40%) with a median duration of survival of 9.5 months (range, 6 + -20). Progressive disease was observed in 9 patients (45%) with a median duration of survival of 6 months (range, 3-25+). Four patients received one course only because of toxicity. One of these patients died at home 6 days after the first course, probably because of dehydration. The main toxicities were myelosuppression, renal impairment, alopecia, and nausea/vomiting. In conclusion, the BIP regimen has considerable toxicity. We were not able to confirm the high response rates earlier reported in pelvic recurrence inside a previously irradiated area. Emphasis in future studies must continue to be placed on the development of more active single agents and combinations. © 1992.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 23 条
[1]   PHASE-II RANDOMIZED TRIAL OF CISPLATIN CHEMOTHERAPY REGIMENS IN THE TREATMENT OF RECURRENT OR METASTATIC SQUAMOUS-CELL CANCER OF THE CERVIX - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].
ALBERTS, DS ;
KRONMAL, R ;
BAKER, LH ;
STOCKNOVACK, DL ;
SURWIT, EA ;
BOUTSELIS, JG ;
HANNIGAN, EV .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (11) :1791-1795
[2]  
BAKER LH, 1978, OBSTET GYNECOL, V52, P146
[3]  
BLACKLEDGE G, 1990, CANCER CHEMOTHER P S, V26, P12
[4]   RANDOMIZED TRIAL OF 3 CISPLATIN DOSE SCHEDULES IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
BONOMI, P ;
BLESSING, JA ;
STEHMAN, FB ;
DISAIA, PJ ;
WALTON, L ;
MAJOR, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) :1079-1085
[5]   COMBINATION CHEMOTHERAPY FOR PATIENTS WITH ADVANCED-CARCINOMA OF THE CERVIX - TRIAL OF MITOMYCIN-C, VINCRISTINE, BLEOMYCIN, AND CISPLATIN [J].
GIANNONE, L ;
BRENNER, DE ;
JONES, HW ;
GRECO, FA ;
BURNETT, LS .
GYNECOLOGIC ONCOLOGY, 1987, 26 (02) :178-182
[6]  
HOFFMAN MS, 1990, GYNECOL ONCOL, V40, P144
[7]  
KAERN J, 1990, Tidsskrift for den Norske Laegeforening, V110, P2759
[8]   A PHASE-II STUDY OF 5-FLUOROURACIL CISPLATINUM IN RECURRENT CERVICAL-CANCER [J].
KAERN, J ;
TROPE, C ;
ABELER, V ;
IVERSEN, T ;
KJORSTAD, K .
ACTA ONCOLOGICA, 1990, 29 (01) :25-28
[9]  
KRAKOFF IH, 1977, CANCER, V40, P2027, DOI 10.1002/1097-0142(197711)40:5<2027::AID-CNCR2820400506>3.0.CO
[10]  
2-A